New Patent Litigation Playbook For Products Switching To Biologics

 
• By Brenda Sandburg

Innovators are losing the protections of ANDA litigation as their products transition from drugs to biologics; both sides in patent disputes will now adopt different strategies.

Transition word on a road sign to illustrate change, improvement or a new way or direction
Transition of insulin and other protein products to biologics will impact patent litigation strategies.

More from Biosimilars

More from Biosimilars & Generics